News
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback